Lenalidomide

Lenalidomide, the active ingredient in Lenalidomide, is an immunomodulatory drug presented as an oral tablet for systemic use. It is indicated for the treatment of adult patients with multiple myeloma and for myelodysplastic syndromes that carry the del(5q) chromosomal abnormality, where it helps control disease progression.

GNH USA supplies Lenalidomide as a licensed, Good Distribution Practice‑compliant product, providing reliable international sourcing for hospitals, oncology centres, pharmacies and clinics worldwide. The product conforms to EU pharmacopeial standards and undergoes rigorous quality testing before release.

Lenalidomide is used in hematologic malignancies that involve abnormal plasma‑cell or myeloid proliferation. - Multiple myeloma: improves progression‑free survival in adult patients. - Myelodysplastic syndromes with del(5q): reduces transfusion dependence and cytopenias. - Relapsed or refractory disease: provides a therapeutic option after prior therapies.

Lenalidomide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced neutrophil count increasing infection risk. - Thrombocytopenia: low platelet count leading to bleeding tendencies. - Fatigue: persistent tiredness affecting daily activities. - Nausea: upset stomach often occurring after dosing. - Diarrhea: loose stools that may require hydration. - Constipation: difficulty passing stools.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Severe neutropenia: profound immune suppression requiring medical intervention. - Serious infections: opportunistic or bacterial infections. - Second primary malignancies: emergence of new cancers. - Hypersensitivity reactions: rash, angioedema, or anaphylaxis.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for known toxicities. - Monitor blood counts: perform regular CBC to detect cytopenias. - Assess thrombotic risk: consider prophylactic anticoagulation in high‑risk patients. - Avoid use in pregnancy: drug is teratogenic; ensure effective contraception. - Renal impairment: adjust dose or monitor renal function closely. - Review concomitant medications: check for interactions that may alter efficacy or safety. - Store at ambient temperature below 25°C: keep in the original container, protect from moisture and light.

Lenalidomide can interact with several agents, requiring careful management.

Major Interactions (Avoid): - Thalidomide: combined use markedly increases thrombosis risk. - Anticoagulants: may enhance anticoagulant effect and bleeding. - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): increase lenalidomide exposure. - Live vaccines: contraindicated due to immunosuppressive potential.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may reduce drug exposure. - NSAIDs: can increase risk of renal toxicity. - Antihypertensives: monitor blood pressure as lenalidomide may affect vascular tone.